In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical ...

Bioanalysis is also used to monitor therapeutic responses by evaluating drug levels, biomarkers, and physiological changes ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

In conclusion, I see 2025 as a year in which the patient will still be centre-stage. But, in order for that to happen ...

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...